American Academy of Optometry
American Academy of Optometry
October 19, 2017
1 min read

Presenter: Screen color vision of every glaucoma patient

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Milton Hom
Milton Hom

CHICAGO – Color vision testing is another way to evaluate patients with glaucoma for functional vision loss, according to Milton Hom, OD, FAAO, in his poster here at the American Academy of Optometry meeting.

Tritan color defects are associated with glaucoma, Hom, a Primary Care Optometry News Editorial Board member, told PCON in an interview.

In his practice, Hom used the ColorDx tablet (Konan), which tests for both tritan (blue-yellow) and congenital (red-green) color vision defects, to determine retrospectively if tritan color defects correlated with visual fields with the Octopus 301 (Haag-Streit) and ganglion cell complex (GCC) optical coherence tomography with the iVue (Optovue).

He evaluated 37 subjects with an average age of about 25 years, according to the study.

“It did correlate with them,” he said. “It correlates with both the 30-2 central field and the 10-2 macular area tests, but it’s higher with the 30-2 test.

“It also correlates with GCC global loss not as strongly, but statistically significantly,” Hom added.

He noted that the test is billable under code 92283.

“Typically, functional loss has only been measured with visual field,” Hom said. “This will also test functional loss. It’s portable, easy to use and relatively inexpensive.”

He concluded: “I would screen every glaucoma patient for progression.” – by Nancy Hemphill, ELS, FAAO


Hom M, et al. Tablet-based color vision testing and glaucoma. Presented at: American Academy of Optometry meeting; Chicago; Oct. 10-14, 2017.

Disclosure: Hom reported no relevant financial interests.